The estimated Net Worth of Charles R Eyler is at least $541 Thousand dollars as of 4 February 2019. Charles Eyler owns over 87 units of Puma Biotechnology Inc stock worth over $79,893 and over the last 12 years Charles sold PBYI stock worth over $460,963.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Charles Eyler PBYI stock SEC Form 4 insiders trading
Charles has made over 10 trades of the Puma Biotechnology Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently Charles sold 87 units of PBYI stock worth $2,405 on 4 February 2019.
The largest trade Charles's ever made was selling 1,322 units of Puma Biotechnology Inc stock on 1 December 2017 worth over $139,418. On average, Charles trades about 427 units every 37 days since 2012. As of 4 February 2019 Charles still owns at least 31,957 units of Puma Biotechnology Inc stock.
You can see the complete history of Charles Eyler stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Charles Eyler's mailing address?
Charles's mailing address filed with the SEC is 10880 Wilshire Blvd, Los Angeles, CA 90024, USA.
Insiders trading at Puma Biotechnology Inc
Over the last 13 years, insiders at Puma Biotechnology Inc have traded over $168,440,369 worth of Puma Biotechnology Inc stock and bought 2,655,298 units worth $48,866,148 . The most active insiders traders include Capital Partners Gp, L.L.C...., Steven Lo, and Troy Edward Wilson. On average, Puma Biotechnology Inc executives and independent directors trade stock every 18 days with the average trade being worth of $60,225. The most recent stock trade was executed by Michael Patrick Miller on 12 August 2024, trading 23,358 units of PBYI stock currently worth $81,519.
What does Puma Biotechnology Inc do?
we focus on in-licensing innovative drug candidates that are undergoing or have already completed initial clinical testing for the treatment of various forms of cancer and then seek to further develop these drug candidates for commercial use.
What does Puma Biotechnology Inc's logo look like?
Complete history of Charles Eyler stock trades at Puma Biotechnology Inc
Puma Biotechnology Inc executives and stock owners
Puma Biotechnology Inc executives and other stock owners filed with the SEC include:
-
Alan H. Auerbach,
Founder, Chairman, Pres, CEO & Sec. -
Jeffrey Jerome Ludwig,
Chief Commercial Officer -
Alan Auerbach,
Chairman of the Board, President, Chief Executive Officer -
Douglas Hunt B.Sc., FRAPS,
Sr. VP of Regulatory Affairs, Medical Writing & Project Management -
Maximo F. Nougues,
CFO & Principal Accounting Officer -
Douglas Hunt,
Senior Vice President, Regulatory Affairs, Medical Writing and Project Management -
Richard Bryce,
Chief Medical and Scientific Officer -
Ann Miller,
Independent Director -
Dr. Richard P. Bryce,
Chief Medical & Scientific Officer -
Maximo Nougues,
Chief Financial Officer -
Hugh O Dowd,
Independent Director -
Jay Moyes,
Lead Independent Director -
Troy Wilson,
Independent Director -
Adrian Senderowicz,
Independent Director -
Michael Miller,
Independent Director -
Mariann Ohanesian,
IR Contact Officer -
Brian Stuglik,
Director -
Dr. Alvin F. Wong,
Chief Scientific Officer -
Charon Spencer Sr.,
VP of HR -
Steven Lo,
Chief Commercial Officer -
Capital Partners Gp, L.L.C....,
-
Robert Charnas,
-
Richard Benton Phillips,
SEE REMARKS -
Charles R Eyler,
SEE REMARKS -
Frank Zavrl,
Director -
Thomas Malley,
Director -
Jeffrey Jerome Ludwig,
Chief Commercial Officer -
Alvin F Wong,
Chief Scientific Officer -
Allison Dorval,
Director -
Alessandra Cesano,
Director